NEW YORK (GenomeWeb News) - Sentigen Holding today said that its stockholders have approved its planned merger with Invitrogen.
Sentigen said it expects the deal to close “within the next several weeks.”
As GenomeWeb News reported in August, Invitrogen said it planned to acquire Sentigen, which includes its subsidiaries Sentigen Biosciences and Cell & Molecular Technologies for
For around $25.9 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.